nce upon a ime there was a coronary device, named «stent» 1 . Its name comes from a dentist 2 , and a noble German prince coming from the battle-field of restenosis and residing Swiss castle help him to become a stronghold of human coronary vessels 3, 4 . Indeed, the stent story is so close to a tale! Since its irst clinical use, with several generaions of stents, throughout years of enthusiasm, complications and drawbacks 5,6 , stents successfully improved to new scafolds. The objecive of this aricle is not to scieniically analyze all the phases of stent development, its clinical applicaion and studies; it is rather to narrate the story as witnessed by a man who has been present from the very beginning.
. Follow-up of 500 paients ater coronary angioplasty (PTCA) -in 1986. Note primary success of only 63% at one year that reaches 78% ater repeat procedures.
in Geneva 9 mainly by new drug treatments using diferent medications, starting with angiogenesis enzyme inhibitors to steroids, but also using technologies such as lasers or atherectomy. I can sill remember a paient that undertook 11 repeated PTCAs for a proximal LAD lesion, someimes restenosed, but mainly caused to balloon injury around the lesion.
Early stents
The Medinvent company located in canton de Vaud, in French Swiss part, was involved with many new technologies, such as ariicial skin. With Prof. Ruisahuser, from Geneva University Hospital, we were invited to discuss the stent experience in 1985 -we had a hall out of a problem to ind locaion of the company installed in Swiss mountains, in the middle of the cows! In spite the work that had already been done by Medinvent, the decision was made to coninue doing only animal study in Geneva before any human experience could be started. It is only that Ulrich Sigwart, of Lausanne University Hospital who had courage to go on! ( Figure 2 , A and B). One must admit that it was not an easy task at all. Just to make it more clear to understand: the unit of Experimental Surgery, in Lausanne disposed of non-opimal x-ray equipment, so some of the experimental dogs (to start the experience) had to be stented in a human catheterisaion laboratory ater regular working hour's (Dr Mirkovitch, experimental surgeon in charge at the ime-personal communicaion).
However, during 1986 total of 19 patients were treated by stent implantaion mainly for restenosis ater PTCA and acute closure, with 3 complicaions due to stent thrombosis 10 . The irst human implantaion was successfully done by Puel in Toulouse early that year in acute seing in a case of abrupt closure. During the irst live stent summit in Lausanne in 1987, the audience could also witness the irst stent thrombosis -while most of the paricipants enjoyed their lunch, Sigwart kept so busy in the Cathlab.
In the years that followed, the Wallstent was being used in several European centres, including Roterdam, London and Geneva ( Figure 3 ) but with disastrous result: from about 100 paients that were treated, stent occlusion occurred in 25 paients, and restenosis in 14 other paients 1, 11 .
The new stent player came from across the Ocean-USA. Richard Schatz had carefully planned and went on doing studies with a balloon expandable model of an ariculated stent 12, 13 , available at that ime in Europe for clinical use, but not in the USA. Colombo implanted successfully irst few stents in 1990, Schatz being present with him in Milan that morning; it happened that Schatz was obliged to leave Milan in the aternoon of the same day, and just ater having let Columbus Hospital for the airport the next stented paient had thrombosis! That made a big impact on Colombo, who was going to abolish the anicoagulaion regimen for years to come. The first bear metal stent (BMS) approved in the USA, was the Giantaurco-Rubin stent 14 . Garry Rubin was working at Emory University, Atlanta, and did some animal studies, but at the same ime authorised studies on paients. However, he pushed too hard for the ime being, got some real problems with the Administraion making the stent program almost abolished. Fortunately, hazard wanted that an US Congress Senator sufered from an acute coronary occlusion and Rubin successfully implanted him a stent. The senator made out of it a personal afair and obtained the stent to be oicially approved (Rubin-personal communicaion).
BMS
The Palmaz-Schatz stent was a relaively rigid device, at irst it had to be hand crimp by the operator on a balloon catheter! The device proved difficulties to be placed at the correct site in tortuous vessel and whan operator tried to pull-back the balloon it was rather a mater of chance that stent stayed on-it. There exists probably no single high-volume operator who has not lost a least one stent in paients' circulaion during the PCI at that ime, but this phenomenon was largely under reported. In order to improve deliverability, an anecdotal alternaive method to stent lesions located in anatomical seings too complex for regular Palmaz-Schatz stent placement was developed in Milan 15 . The method consist of using a disarticulated (one-half) Palmaz-Schatz stent -as a mater of fact, Colombo ( Figure 4 ) "simply" decided to cut a stent by half at the site of ariculaion! He obtained signiicant results in delivering the stent on the exact place of coronary lesion.
The world society of intervenional cardiology welcomed the arrival of new stent designs e.g technical details of 17 stent models are presented, in the book of P.W. Serruys 16 on coronary stents in 1997. Not only the stent designs and material have evolved over years, but the implantaion technique has signiicantly developed producing a major successful impact. The use of high-pressure balloon inlaion (HP), intravascular ultrasound (IVUS) and appropriate aniplatelet therapy have contributed to the abolishment of the need for subsequent anicoagulaion, allowing extended stent applicaions 17, 18 . These changes are best shown by Dr Colombo who pioneered this technique 19 . To illustrate that ( Figure 5 ), we compared three groups of paients 20 having stent implantaion throughout the period of technical evoluion Group A: no IVUS, no HP, with subsequent anicoagulaion treatment (n = 434); group B: no IVUS, yes HP, without subsequent anicoagulaion treatment (n = 192); and group C: yes IVUS, yes HP, without subsequent anicoagulaion treatment (n = 588). The primary success rates were comparable in all groups. There was a clear change in indicaions for stening in groups B and C compared with group A (elecive stening: A= 32%; B = 66%; C = 69%; P < 0.0001), in reference vessel size (A = 3.22 mm; B =2.92 mm; C=2.98 mm; P < 0.0001), and for presence of type B2 and C lesions (A = 57%; B = 72%; C = 74%; P < 0.001). The complicaion rate signiicantly decreased in group C (A = 3.6%; B = 4.1%; C = 1.2%; P < 0.001) and the mean paient hospital stay decreased to 2 days in groups B and C due to the aboliion of the need for anicoagulant treatment. The angiographic restenosis rate increased in groups B and C (A=20%; B =34%; C = 32%; P < 0.001). The need for a repeat procedure increased as stening of more complex lesions and smaller vessels was atempted: target lesion revascularizaion (TLR) was performed in 16% of paients in group A, in 18% of group B and in 22% of group C (P= 0.04 for A versus C). Major cardiac events (MACE) occurred in 30-33% in different groups. The evolving technique of coronary stening has expanded the spectrum of indicaions and range of coronary vessels atempted, and decreased the complicaion rates and hospital stay. However, in less-favourable subsets, addiional improvements were needed to afect the long-term outcome 21 . These improvements had to wait the introducion of DES.
Indeed, a word should be said about abolishing the anicoagulaion treatment -A.Colombo reported the irst 80 paients with only aspirin and Ticlopidine treatment ater successful stening in early 1993, just in the course of intensive recruitment of paients for Benestent study, and had a hell of diiculty to convince the European community to adopt the aitude. For example, P. Serruys openly said to him "you will fall from the Himalaya Pick if you are wrong..." and he literary meant that 22 . However, the hard data with IVUS study, corroborated with help of Jonathan Tobis from UCLA led to the internaional recogniion and implementaion of Colombo's technique. 
deS
With the expanded indicaions for the use of BMS, such as being a case in small vessel, long-lesions, bifurcaions, and diabeics, two major limitaions of BMS became cumbersome: subacute stent thrombosis (ST) and stent restenosis with a need for target vessel revascularizaion (TVR). The metallic stainless steel cage of BMS stent produced a binary stent restenosis of 35-50% independently of stent model 23 . The brachyterapy was applied in large volume centres -but it was unsuitable (a cathlab in a cathlab!), in paricular producing late thrombosis, geographic mismatch, relaively high cost, and requirement of radiaion oncologists. Drug-eluing stents (DES) were developed to speciically address the problems of restenosis encountered with BMS ( Table 1) . The device dispose with three components: metallic plaform, polymer coaing and aniproliferaive drugs ( Figure 6 ).
The first successful DES trials were using Cypher (Cordis Corp, Johnson and Johnson Company, Miami, FL, USA) which led to its approval 24 ,25 in Europe in 2002. Soon aterwords, a series of trials enabled commercialisaion of paclitaxel eluing Taxus stent (Boston Scieniic, Natrick, MA, USA), in 2004. The paclitaxel had somehow higher TLR rate and was used in several studies in the years to come as "non-inferior" stent permiing commercialisaion of a new stents of second generaion 26 , The Xience V (Abbot, IL, USA) everolimus eluing stent was approved and has been available on market since late 2006. The market penetraion of stents was very rapid in Switzerland 27 , only in the course of the year1996 about 50% of PCI, up to 78% in 2000, and 91% in 2007. Second-generaion DES stents have reinod all of the three components: the struts, polymers, and drugs eluted, thereby improved outcomes. Compared with the irst generaion DES, second-generaion devices 28 lowered the risk of ISR, ST, and mortality. For example 29 , the Swedish Registry on 94.384 patients found 38% lower risk of restenosis, a 43% lower risk of deinite ST, and a 23% lower risk of death compared to irst genera- Currently, the last generaion of stent need only 3 months of DAPT, bioapsorbale coaing is only on abluminal side of stent, struts are thin and metallic cage is laser cut hypotube. A novel bio absorbable polymer everolimus-eluing stent Synergy (Boston Sc.) was compared with the durable polymer Promus Element. At follow-up of two years 28 , target lesion failure was non-inferior (6.1% for Promus vs. 5.5% for Synergy) with no ST.
There were two events that should be menioned. In 2006, at the World Congress of Cardiology in Barcelona, E. Camenzind presented 30 the results of a meta-analysis of randomized clinical studies comparing DES versus BMS, reporing greater incidence of total mortality and Q-wave MI for DES (38% versus 16% respecively). Camenzind concluded: "unil safer second-generaion DES is available, intervenional cardiologist should avoid its indiscriminate use"! I was atending the lecture with Dr Colombo who told me while geing out of the conference room: "Thanks good I have got involved in wine 31 producion". As a mater of fact, the stent implantaion rate went down the irst time since introduction of DES. Only in the USA it de- The second event happened during the American College of Cardiology Meeing in 2007 where result of the "Courage" study were presented at the morning Hot-Session showing equality of stening versus medical treatment in patients with stable angina 32 . During a panel discussion, the evening before oicial study presentaion, Marin Leon publically discovered the study results, correctly undermining its importance -this made more publicity than the study itself! Dr Leon was suspended from ACC aciviies for two years, just as an excellent football player.
Industrial involvment
No story in the world is complete without talking about money. The Medinvent stent patent was acquired for about 1 million SFR in 1988 by Schneider Medintag AG, a Swiss company producing balloon catheters, led by Heliane Canepa (who was later honoured the Swiss business woman of the year). The unfavourable result of a mulicentre study that followed in 1991 damped this stent for coronary use. The Johnson & Johnson Company (J&J) was the first to market the "Palmaz-Schatz" stent, for a sale price about 2.000 dollars a piece. By 1996 the J&J sold approximate one million stents worldwide with virtually no any compeiion 33 . Saying that reminds me that, as all authors, I have to relieve my inancial disclosures -that unfortunately are none. The market for stents was growing rapidly as coronary stening overtook PTCA by 1997.
The other medical company, Boston Scieniic (BS), which has lost an opportunity to license the Palmaz-Schatz stent, needed a stent to remain a viable player in the ield. So, they had explored relaions with other small companies owning stent technology. A sloted tube NIR stent has been designed in Israel by Medinol Company of Kobbi Richter. The stent has many technical advantages over Palmaz -Schatz stent, including lexible closed cell design, improved deliverability and lexibility, and length: 35mm long stent compared to 15mm standard. In 1995, BS and Medinol have entered into a series of agreements, followed by a low suite. The NIR Stent was used in Europe in 1996 and introduced to the U.S. two years later. It quickly became a major part of BS business. By year 2000, NIR stent sales have grown to about 600 million dollars in worldwide revenue 34 . As a result, Medinol a small startup company has become major player. Case setlement was done by 2005 for 750 million dollars.
DES development and numerous new model (about 30 diferent Stent in Europe), made the market parts to be shared. The J&J announced in 2011 abandoning their coronary stent business, just a year ater desperate tentaive of buying Connor Medsystems for $1.4B who had developed a beauiful stent model with double drug "reservoirs". The sales of J&J dropped from $2.62 billion in 2006 to only $627 million in 2012, making the end of the successful inancial story.
A case of chronic total coronary occlusion (CTO)
The raional of opening chronic occlusion is nowadays extremely well established and the one ime scepicism of "having an open artery" is over 35 . Paients with an open artery are not only doing well at medium-term compared to the ones with unsuccessful procedure, but their long-term results up to 20 years are improved. Technical advancement in recanalisaion material wires and catheters has allowed for the high procedure success but the long-term beneit ater stent implantaion is clearly due to the new stent development.
We published one of the irst aricles that demonstrated beneit in paients with successful PTCA of CTO in Geneva Centre 36 . However, coronary angioplasty of CTO has been associated with disappoining resultsprimary success was only 60-70% and restenosis rate up to 50% leading to the long term-success in less than half of iniially treated populaion ( Figure 6 ). Technical advancement in wires and material made litle impact on results at that ime e.g., Magnum wire 37 . The introducion of BMS has improved restenosis rate, sill plafond above 20%, with many paients presening new reclusion at follow-up angiography. The early aricle in 1995, using BMS published with Dr Colombo, showed sill limited improvement with a clinical beneit in about 77% of paients at follow-up 38 . In a Mulinaional CTO Registry 39 on 1.226 paients followed-up to 5 years, the TLR was lower in DES group compared to BMS group (17.2 versus 31.1%, p<0.01). A small Canadian study 40 in 159 paients showed improved event-free survival at 5 years with DES compared to BMS (89.4% versus 74.8% respecively). The advancements in technology of guide-wires, micro-catheters and introduction of retrograde approach for recanalisaion, in paricular coming from Japan, allowed the success rate to increase substanially (currently in an expert hands close to 90%, O.Katohpersonal communicaion). At the same ime, with systemaic implantaion of DES long-term result improved with restenosis rate below 10% (Figure 7 In one study 41 the everolimus-eluing stents were associated with a signiicantly lower reocclusion rate than were other drugeluting stents (3.0% vs. 10.1%; p = 0.001). New DES stents, currently called the 4 th generaion can even further decrease the recurrence, to less than 10%. The future use of BVS in CTO is certainly challenging, but our excitement at present should be tempered.
Bioresorbable vascular scafolds (BVS)
Bioresorbable vascular scafolds (BVS) are intended to overcome most drawbacks of stents: the permanent presence of a metallic cage that stays on the vessel wall beyond its intended purpose prevening acute recoil and late lumen expansion, posiive remodelling, impair vessel geometry and normal vasomotor vessel funcion, and interface with MRI or MRC. A decrease restenosis and stent thrombosis rates as compared with convenional (metallic) stents is possible. Furthermore, the vessel access for eventual future coronary bypass grating is maintained 42 .
The use of BVS has largely been in the context of simple proximal lesions of vessel 2.5-4.0mm in clinical trials, but the indicaions have expanded to more complex lesions of 'real-world' including long and difuse disease. At present, three scafolds models are available for clinical use.
The balloon expandable Absorb device (Abbot Vascular, Santa Clara, California, US) made from semicrystalline poly-L-lacic acid (PLLA) coated with an amorphous poly-D, L-lacide (PDLA) polymer eluing everolimus, has two plainum markers that allow x-ray visualizaion. The single strut thickness is 156 microns, is desorbed in 2-3 years. The Absorb stent is commercially available in Europe.
The Dreams device (Biotronic, Bulach, Switzerland) is a balloon expandable, paclitaxel-eluing magnesium alloy-based bioresorbable coronary stent. The implant is radiolucent and has a single strut thickness of 125 microns. The absorpion process takes 9-12 months. Mechanical properies are similar to the current generaion of metallic stents including safe over dilataion. It soon receives a CE mark.
The DeSolve stent (Elixir Medical, Sunnyvale, California, US) provides suicient radial strength for over 3 months and is fully desorbed in 1-2 years. Self-apposant properies allow to over expanding (for 1 mm without evidence of strut fracture). The Desolve stent received a CE mark in 2013.
Most studies have been done with the Absorb BVS with good clinical results reported up to four years 43 . The Scafold area by OCT was shown to progressively increase during follow-up with no diferences in late lumen loss. The TLR and MACE rates at one-year have been reported as 1.8 and 4.2 %, respectively. Stent thrombosis rate was 0.9 %. The ongoing Absorb III and IV studies (2250 and 3000 paients, respecively) aim to compare Absorb BVS to Xience Everolimus Eluing Stent (Abbot Vascular, Santa Clara, California, US).
The view of BVS antagonists, such as Haim Lotan's from Hadassah Hospital, Israel includes absence of long-term results, current unsuitability for bifurcaions, small vessel, or long lesion and of course good result with last generaion DES stent. The consensus opinion of Greg Stone is probably the most appropriate at present, keeping with recommended indicaions for all type of devices 44 . 
